Real-world Characteristics, Treatments and Outcomes of NATALEE and monarchE-Eligible HR+/HER2- Early Breast Cancer Patients in the Hospital District of Helsinki and Uusimaa (HUS), Finland

Sari Voutilainen^1,2, Samuli Tuominen³, Sari Hernesniemi⁴, Mia Engström-Risku⁴, Liisa Ukkola-Vuoti³, Juhani Aakko³, Björn Paulsson⁵, Maija Wolf⁴, Peeter Karihtala^1,2

^{1 Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
2 University of Helsinki, Helsinki, Finland
3 Medaffcon Oy, Espoo, Finland
4 Novartis Finland Oy, Espoo, Finland
5 Novartis Sverige AB, Stockholm, Sweden}